Day One

• Standardising non‑canonical amino acids, a scaffold‑driven monomer nomenclature and a centralised, harmonised database (>7000 standardised monomers) provide a consistent, machine‑readable representation that links chemical structures and sequence notation.
• Integrating standardisation across the DMTA cycle, governed submission‑and‑review workflows and cross‑platform connections (design, registration, and analysis tools) embed consistent monomer representation into routine peptide work, reducing ambiguity and improving data quality for decision‑making.
• Supporting computer‑aided and AI‑based design, a structured, high‑quality data foundation provides the input required for machine learning and computer‑aided design, and improves cross‑functional consistency in peptide programs, contributing to more efficient peptide optimisation.

• Explore how AI-driven co-folding approaches are enabling the rational design of synthetic macrocyclic peptides against challenging therapeutic targets.
• Discover how integrating computational modelling with medicinal chemistry and experimental biology can improve hit quality, accelerate optimisation, and strengthen confidence in candidate selection.
• Gain insights into building multidisciplinary discovery workflows that leverage AI to unlock next-generation macrocyclic peptide therapeutics.

• Understand the relationship between molecular weight, polar surface and membrane permeability to enable accessing intracellular targets and formulation-free approaches to oral delivery.
• Library synthesis and screening methods for de novo generating membranepermeable cyclic peptides to targets of choice.
• Gain insights into selecting the right macrocycle format for protein-protein interaction targets.

Join our speed networking session designed exclusively for peptide discovery, chemistry, formulation, CMC and manufacturing leaders. Connect with peers tackling similar scientific and development challenges, exchange ideas on emerging opportunities and build valuable relationships with the people driving the next generation of peptide therapeutics.

• Target-directed screens in mammalian cells to identify cyclic peptide inhibitors of a given protein–protein interaction.
• Hit-to-lead optimisation of cyclic peptides, including scaffold-hopping the pharmacophore into small-molecule backbones.
• Target-agnostic phenotypic screens with a genetically encoded cyclic peptide library to identify synthetic-lethal ligands and new targets.

• Explore how cyclic peptide-based degraders are expanding the therapeutic landscape by enabling the selective degradation of disease-driving proteins beyond the reach of conventional small molecules.
• Understand the key design principles for engineering peptide degraders with improved target specificity, intracellular activity, and therapeutic potential.
• Discover emerging opportunities and translational challenges in applying peptide-based targeted protein degradation across oncology and other high-value therapeutic areas.

• Exploring the unique advantages of cyclic peptides and their growing importance in addressing challenging therapeutic targets.
• Understanding when and why mammalian display systems are critical for identifying and optimising peptides against complex targets.
• Showcasing Curve Therapeutics’ innovative platform and recent progress in expanding the possibilities of cyclic peptide drug discovery and development.

• Explore how peptide-based delivery technologies are enabling targeted delivery of antisense oligonucleotides (ASOs) to extrahepatic tissues, including the lung and oncology indications.
• Discover strategies for overcoming tissue-specific delivery barriers to improve cellular uptake, therapeutic efficacy, and target engagement.
• Examine case studies demonstrating how peptide conjugates are expanding the clinical potential of oligonucleotide therapeutics across previously inaccessible disease areas.

• Discover how advances in structural biology and target validation are enabling peptides to address previously inaccessible disease pathways.
• Explore strategies for improving target selectivity while reducing off-target toxicity and enhancing therapeutic efficacy.
• Examine case studies demonstrating how next-generation peptide design is unlocking first-in-class therapeutic opportunities across multiple disease areas.

• Explore how high-throughput GI permeability and stability screening platforms accelerate lead selection and optimal drug delivery system to maximise oral bioavailability.
• Understand the complex relationship between peptide API structure and drug delivery systems affecting oral exposure.
• Discover how integrating high throughput screening with computational tools can advance lead selection and rapid identification of optimal drug delivery system.
• Assessment potential of AI-ML enabled tools leveraging multidimensional data (permeability, stability, dissolution, and oral PK) to accelerate the development of peptide APIs and formulations optimised for maximal oral exposure.

A chance to highlight your latest research, raise the profile of your work and connect with fellow innovators tackling the biggest challenges in peptide therapeutics. Exchange ideas, gather feedback and establish new collaborations while exploring cutting-edge science from across the European peptide community.